Future Oncol. 2010;6(5):665-679. Three Phase I studies by O'Donnell and colleagues have reported the pharmacodynamic activity of abiraterone acetate, which was originally developed as an oral ...

Androgen receptor signaling remains important in castration-resistant prostate cancer (CRPC) as demonstrated by the efficacy of abiraterone acetate (henceforth abiraterone) in phase III trials. Given ...

Please provide your email address to receive an email when new articles are posted on . Adding abiraterone acetate to androgen deprivation therapy plus docetaxel improved radiographic PFS and OS among ...

Please provide your email address to receive an email when new articles are posted on . Two years of abiraterone acetate plus prednisolone-based therapy significantly improved survival among men with ...

Postoperative Adjuvant Anastrozole for 10 or 5 Years in Patients With Hormone Receptor–Positive Breast Cancer: AERAS, a Randomized Multicenter Open-Label Phase III Trial Metastatic ...

BEERSE, Belgium--(BUSINESS WIRE)--The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of a Marketing Authorisation Application (MAA) to the European Medicines ...

Credit: Getty Images. The application is supported by data from a phase 3 study evaluating niraparib plus AAP as first-line treatment in patients with mCRPC with or without alterations in HRR ...

Low-dose AA with low-fat breakfast had greater effect on PSA; similar effect to standard dose HealthDay News — For castration-resistant prostate cancer (CRPC), low-dose abiraterone acetate (AA) with a ...

On January 14, 2020, the Federal Court released a decision by Phelan J. in patent infringement actions pursuant to subsection 6(1) of the Patented Medicines (Notice of Compliance) Regulations (PMNOC ...

Future Oncol. 2010;6(5):665-679. Given the efficacy and tolerability of abiraterone acetate, further studies of abiraterone acetate in combination with other chemotherapeutics and biologic agents are ...